Cargando…

Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial

INTRODUCTION: Clinical effects of furosemide (F) and ethacrynic acid (EA) continuous infusion on urine output (UO), fluid balance, and renal, cardiac, respiratory, and metabolic function were compared in infants undergoing surgery for congenital heart diseases. METHODS: A prospective randomized doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Zaccaria, Haiberger, Roberta, Pezzella, Chiara, Garisto, Cristiana, Favia, Isabella, Cogo, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305226/
https://www.ncbi.nlm.nih.gov/pubmed/25563826
http://dx.doi.org/10.1186/s13054-014-0724-5
_version_ 1782354197780365312
author Ricci, Zaccaria
Haiberger, Roberta
Pezzella, Chiara
Garisto, Cristiana
Favia, Isabella
Cogo, Paola
author_facet Ricci, Zaccaria
Haiberger, Roberta
Pezzella, Chiara
Garisto, Cristiana
Favia, Isabella
Cogo, Paola
author_sort Ricci, Zaccaria
collection PubMed
description INTRODUCTION: Clinical effects of furosemide (F) and ethacrynic acid (EA) continuous infusion on urine output (UO), fluid balance, and renal, cardiac, respiratory, and metabolic function were compared in infants undergoing surgery for congenital heart diseases. METHODS: A prospective randomized double-blinded study was conducted. Patients received 0.2 mg/kg/h (up to 0.8 mg/kg/h) of either F or EA. RESULTS: In total, 38 patients were enrolled in the F group, and 36, in the EA group. No adverse reactions were recorded. UO at postoperative day (POD) 0 was significantly higher in the EA group, 6.9 (3.3) ml/kg/h, compared with the F group, 4.6 (2.3) ml/kg/h (P = 0.002) but tended to be similar in the two groups thereafter. Mean administered F dose was 0.33 (0.19) mg/kg/h compared with 0.22 (0.13) mg/kg/h of EA (P < 0.0001). Fluid balance was significantly more negative in the EA group at postoperative day 0: −43 (54) ml/kg/h versus −17 (32) ml/kg/h in the F group (P = 0.01). Serum creatinine, cystatin C and neutrophil gelatinase-associated lipocalin levels and incidence of acute kidney injury did not show significant differences between groups. Metabolic alkalosis occurred frequently (about 70% of cases) in both groups, but mean bicarbonate level was higher in the EA group: 27.8 (1.5) M in the F group versus 29.1 (2) mM in the EA group (P = 0.006). Mean cardiac index (CI) values were 2.6 (0.1) L/min/m(2) in the F group compared with 2.98 (0.09) L/min/m(2) in the EA group (P = 0.0081). Length of mechanical ventilation was shorter in the EA group, 5.5 (8.8) days compared with the F group, 6.7 (5.9) (P = 0.06). Length of Pediatric Cardiac Intensive Care Unit (PCICU) admission was shorter in the EA group: 14 (19) days compared with 16 (15) in the F group (P = 0.046). CONCLUSIONS: In cardiac surgery infants, EA produced more UO compared with F on POD0. Generally, a smaller EA dose is required to achieve similar UO than F. EA and F were safe in terms of renal function, but EA caused a more-intense metabolic alkalosis. EA patients achieved better CI, and shorter mechanical ventilation and PCICU admission time. TRIAL REGISTRATION: Clinicaltrials.gov NCT01628731. Registered 24 June 2012.
format Online
Article
Text
id pubmed-4305226
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43052262015-01-25 Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial Ricci, Zaccaria Haiberger, Roberta Pezzella, Chiara Garisto, Cristiana Favia, Isabella Cogo, Paola Crit Care Research INTRODUCTION: Clinical effects of furosemide (F) and ethacrynic acid (EA) continuous infusion on urine output (UO), fluid balance, and renal, cardiac, respiratory, and metabolic function were compared in infants undergoing surgery for congenital heart diseases. METHODS: A prospective randomized double-blinded study was conducted. Patients received 0.2 mg/kg/h (up to 0.8 mg/kg/h) of either F or EA. RESULTS: In total, 38 patients were enrolled in the F group, and 36, in the EA group. No adverse reactions were recorded. UO at postoperative day (POD) 0 was significantly higher in the EA group, 6.9 (3.3) ml/kg/h, compared with the F group, 4.6 (2.3) ml/kg/h (P = 0.002) but tended to be similar in the two groups thereafter. Mean administered F dose was 0.33 (0.19) mg/kg/h compared with 0.22 (0.13) mg/kg/h of EA (P < 0.0001). Fluid balance was significantly more negative in the EA group at postoperative day 0: −43 (54) ml/kg/h versus −17 (32) ml/kg/h in the F group (P = 0.01). Serum creatinine, cystatin C and neutrophil gelatinase-associated lipocalin levels and incidence of acute kidney injury did not show significant differences between groups. Metabolic alkalosis occurred frequently (about 70% of cases) in both groups, but mean bicarbonate level was higher in the EA group: 27.8 (1.5) M in the F group versus 29.1 (2) mM in the EA group (P = 0.006). Mean cardiac index (CI) values were 2.6 (0.1) L/min/m(2) in the F group compared with 2.98 (0.09) L/min/m(2) in the EA group (P = 0.0081). Length of mechanical ventilation was shorter in the EA group, 5.5 (8.8) days compared with the F group, 6.7 (5.9) (P = 0.06). Length of Pediatric Cardiac Intensive Care Unit (PCICU) admission was shorter in the EA group: 14 (19) days compared with 16 (15) in the F group (P = 0.046). CONCLUSIONS: In cardiac surgery infants, EA produced more UO compared with F on POD0. Generally, a smaller EA dose is required to achieve similar UO than F. EA and F were safe in terms of renal function, but EA caused a more-intense metabolic alkalosis. EA patients achieved better CI, and shorter mechanical ventilation and PCICU admission time. TRIAL REGISTRATION: Clinicaltrials.gov NCT01628731. Registered 24 June 2012. BioMed Central 2015-01-07 2015 /pmc/articles/PMC4305226/ /pubmed/25563826 http://dx.doi.org/10.1186/s13054-014-0724-5 Text en © Ricci et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ricci, Zaccaria
Haiberger, Roberta
Pezzella, Chiara
Garisto, Cristiana
Favia, Isabella
Cogo, Paola
Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
title Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
title_full Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
title_fullStr Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
title_full_unstemmed Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
title_short Furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
title_sort furosemide versus ethacrynic acid in pediatric patients undergoing cardiac surgery: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305226/
https://www.ncbi.nlm.nih.gov/pubmed/25563826
http://dx.doi.org/10.1186/s13054-014-0724-5
work_keys_str_mv AT riccizaccaria furosemideversusethacrynicacidinpediatricpatientsundergoingcardiacsurgeryarandomizedcontrolledtrial
AT haibergerroberta furosemideversusethacrynicacidinpediatricpatientsundergoingcardiacsurgeryarandomizedcontrolledtrial
AT pezzellachiara furosemideversusethacrynicacidinpediatricpatientsundergoingcardiacsurgeryarandomizedcontrolledtrial
AT garistocristiana furosemideversusethacrynicacidinpediatricpatientsundergoingcardiacsurgeryarandomizedcontrolledtrial
AT faviaisabella furosemideversusethacrynicacidinpediatricpatientsundergoingcardiacsurgeryarandomizedcontrolledtrial
AT cogopaola furosemideversusethacrynicacidinpediatricpatientsundergoingcardiacsurgeryarandomizedcontrolledtrial